Modeyso (dordaviprone) — Medica
High-grade glioma (including diffuse midline glioma or glioblastoma)
Initial criteria
- Patient has a histone 3 (H3) K27M mutation
- Patient has recurrent or progressive disease
- Patient has received at least one prior therapy (e.g., radiation, temozolomide, procarbazine, lomustine, or vincristine)
Approval duration
1 year